| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Investor sentiment often swings with the ebb and flow of clinical trial results, technological advancements, and strategic corporate partnerships. In this volatile environment, market analysts and financial commentators provide crucial guidance to help navigate the complex landscape of investment opportunities.
On CNBC's “Mad Money Lightning Round,” Jim Cramer said no to Viking Therapeutics, Inc. (NASDAQ:VKTX).
On Tuesday, Viking Therapeutics released the much-awaited data from its Phase 2 trial of VK2735 pill, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
Cramer still expects Palantir Technologies Inc. (NASDAQ:PLTR) to go to $200.
As per the recent news, the company, on Sept. 4, announced a five-year extension with Lear Corp. (NYSE:LEA), a new collaboration with Lumen Technologies (NYSE:LUMN), and plans for its upcoming AIPCon 8 event in September 2025.
“You buy it, but you recognize that it's your spec,” Cramer said when asked about Richtech Robotics Inc. (NASDAQ:RRR). “Accept the fact that you could lose everything.”
Richtech Robotics, on Aug. 28, announced a $100 million at-the-market offering.
Price Action:
Read Next:
Photo: Shutterstock
